Trials / Completed
CompletedNCT00651911
Fasturtec TLS Treatment / Prophylysis
A Multicenter Open Label Study of the Efficacy and Safety of Rasburicase in the Treatment of Prophylysis for Tumor Lysis Syndrome
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open-label study to determine the efficacy and safety of Rasburicase used for the prevention and treatment of tumor lysis syndrome
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | urate oxidase | First injection of Rasburicase will be done the day of initiation of chemotherapy, or the day before, according to hyperuricemia. Additional doses are permitted q12h during the first 72 hours of chemotherapy if hyperuricemia persists or subject is considered to be at significant risk of tumor lysis complications. |
Timeline
- Start date
- 2003-07-01
- Completion
- 2004-07-01
- First posted
- 2008-04-03
- Last updated
- 2008-04-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00651911. Inclusion in this directory is not an endorsement.